ABOUT THERMO FISHER SCIENTIFIC
Thermo Fisher is a leading global provider of bioprocessing solutions. We simplify the development path and accelerate our customers’ innovations to bring therapies to patients, faster. With our comprehensive portfolio of products and services we are a dedicated partner throughout the biological drug development journey.
Key Capabilities:
- Media and buffer preparation
- Cell expansion
- Cell culture production
- Harvest
- Capture and polish chromatography
- Viral inactivation, filtration, and QC testing
- Bulk storage, fill, and finish
- cGMP chemicals and supply chain services
- Expert professional support to meet process, scale, quality, and regulatory requirements
CONTACT INFORMATION
Thermo Fisher Scientific
7305 Executive Way
Frederick, MD 21704
UNITED STATES
Contact: Hunter Tuck
FEATURED SOLUTIONS
-
Closed, automated T cell isolation with greater than 85% efficiency and greater than 96% purity is now achievable in 70 to 100 minutes, with cGMP-ready scalability from research to clinical manufacturing.
-
Whole blood offers a faster, lower-cost starting material for T cell isolation and CTS Detachable Dynabeads CD4/CD8 with the DynaCellect System make it a viable, cGMP-aligned option without preprocessing.
-
Active bead release gives manufacturers precise control over T cell isolation timing, phenotype preservation, and workflow efficiency, eliminating multi-day passive dissociation delays.
-
Bead-free T cell activation is now achievable with a soluble, GMP-compliant format that supports up to 1.5 billion cells per vial, decouples activation from isolation, and removes with a simple cell wash.
-
Residual CD3+ cells shouldn't be the bottleneck in your allogeneic therapy workflow. This prototype achieves <0.5% residual T cells at commercial-scale processing capacity.
-
Explore how strategic resin and buffer selection enhances AAV purification efficiency, from affinity capture that reduces processing steps to anion exchange methods that separate full capsids.
-
Learn how optimized resin and buffer combinations improve mAb purification efficiency, helping you achieve stringent quality standards while extending resin lifetime and reducing costs.
-
Optimize mRNA purification yield and purity with compatible resin and buffer combinations for therapeutic applications, supported by cGMP-compliant chemical supply chains.
FEATURED INSIGHTS
-
A CHO-S bispecific antibody program needed a better basal and feed media combination. Learn how the screening of 180 conditions in 12 weeks identified one that delivered 38% higher titers.
-
Learn how closed-system automation, combined with expert technical guidance and protocol optimization, turned a persistent manufacturing bottleneck into a reliable, scalable process.
-
Lithium heparin reduces T cell purity to below 50% and spikes CD15+ contamination in whole blood workflows. See which anticoagulants consistently deliver above 90% CD3+ purity.
-
Facility space costs up to $1,000/sq ft and planning timelines stretch 18 months, making your adherent cell culture platform choice one of the highest-stakes decisions in vaccine manufacturing scale-up.
-
Manufacturing flexibility is now a competitive differentiator. Here's how single-use technologies are reshaping bioprocessing facility design, scalability, and sustainability strategy.
-
Batch-to-continuous transitions in downstream bioprocessing carry real risks. Here's how advanced analytics, smarter buffer strategies, and single-use systems are changing that calculus.
-
Choosing a cell culture media supplier is crucial in biopharmaceutical manufacturing. Explore five key factors to take into account when choosing a supplier and evaluating their capabilities.
-
Discover four essential bioprocess scale-up criteria and how each balances hydrodynamics, shear, and mass transfer across manufacturing scales.